GHRS Stock Summary and Trading Ideas (GH Research PLC - | NASDAQ:GHRS)

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

GH Research PLC - trades on the NASDAQ stock market under the symbol GHRS.

As of October 22, 2026, GHRS stock price declined to $18.50 with 318,007 million shares trading.

GHRS has a beta of 1.68, meaning it tends to be more sensitive to market movements. GHRS has a correlation of 0.13 to the broad based SPY ETF.

GHRS has a market cap of $1.27 billion. This is considered a Small Cap stock.

In the last 3 years, GHRS traded as high as $31.44 and as low as $5.05.

The top ETF exchange traded funds that GHRS belongs to (by Net Assets): IBB, PSIL, EIRL, BBC, IBBQ.

GHRS has outperformed the market in the last year with a return of +45.0%, while the SPY ETF gained +14.9%. However, in the most recent history, GHRS shares have underperformed the stock market with its stock returning -34.7% in the last 3 month period and -12.2% for the last 2 week period, while SPY has returned +2.3% and -1.7%, respectively.

GHRS support price is $18.13 and resistance is $19.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GHRS shares will trade within this expected range on the day.